Lower dosing of Loxoprofen in type two diabetics with bone fractures/surgeries; Distinction from common NSAIDs

To investigate the appropriateness of lower doses of loxoprofen in patients with type two diabetes (T2D) with bone fractures/surgeries in comparison to common NSAIDs.

The current study is a prospective cross-sectional study. A total of 174 patients treated for bone fractures/orthopedic surgeries were recruited from orthopedic outpatient clinics in Amman, Madaba, and University of Jordan Hospital. Risk stratifications were performed for cardiovascular (CV), gastrointestinal (GI), renal, and hepatic complications. We created in-depth comparisons of safety and effectiveness of common NSAIDs in alleviating postoperative/ fracture pain.

All NSAIDs showed variable reductions in the numerical pain score (NPS) after four weeks. Loxoprofen was the only NSAID prescribed at lower daily doses of 60-120 mg. Loxoprofen resulted in the most reduction in NPS; the fastest onset of action; the least time to reach peak analgesia; decrease in nocturia and the strongest overall pain relief in bone fractures and postoperative pain, p < 0.05. Celecoxib had the highest variability in pain relief among the agents.

Lower doses of loxoprofen provide an effective strategy to alleviate postoperative and bone fracture pain and increase patient satisfactions among T2D at lower systemic risks compared to other NSAIDs. Such low dosing approach provides a plausible balanced triad of safety, effectiveness and maximum bone healing which lead to maximum patient satisfaction.